tiprankstipranks
Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties
Company Announcements

Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties

Don't Miss our Black Friday Offers:

Aclaris Therapeutics (ACRS) has provided an update.

Aclaris Therapeutics has struck a lucrative deal with OMERS, selling a portion of its future royalty payments and associated milestones from its license with Eli Lilly for OLUMIANT, a treatment for alopecia areata. The transaction nets Aclaris an immediate $26.5 million, with the potential for an additional $5 million, depending on sales achievements in 2024. OMERS, in return, gains a slice of the ongoing royalty pie from global sales of OLUMIANT, reinforcing its investment portfolio in the healthcare sector. This strategic financial move was also publicized through a press release to keep investors informed.

For an in-depth examination of ACRS stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyAclaris upgraded at Cantor after deal adds two ‘potential blockbusters’
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App